Stocks To Buy Now

Blog

The Stocks To Buy Now Blog

Our team has been covering the micro- and small-cap markets for more than a decade, exploring a wide variety of trends, technology and news in every industry. The Stocks to Buy Now blog seeks out undervalued companies, covers their news, breaks down the jargon, and delivers accurate and timely information to you on a daily basis.

If you’re looking for market insight, undervalued gems, and an assortment of investment options, read on.

Discovery Ventures, Inc. (DTVMF) Pushing toward Commencement of Mining Operations at WillaMax Gold Project

Discovery Ventures, Inc. (OTCQX: DTVMF) is an exploration and development stage mining company focused on the WillaMax gold project in southeast British Columbia, Canada. The Willa property is highly developed, with current measured and indicated resources of over 758,000 metric tons grading 6.67 grams of gold per unit. The Max project, which is located approximately […]

ImmunoCellular Therapeutics, Ltd. (IMUC) Preparing to Address Underserved Market through Development of Leading Product Candidate

ImmunoCellular Therapeutics, Ltd. is a clinical stage biotechnology company developing immune-based therapies for the treatment of brain and other cancers. The company’s leading product candidate, ICT-107, is a vaccine that targets antigens associated with glioblastoma multiforme (GBM), the most common and lethal form of brain cancer. In recent weeks, ImmunoCellular has made progress toward the […]

Cibolan Gold Corp. (CIBG) Rapidly Approaching Start of Production at Independence Mining Project

Cibolan Gold is an aggressive junior mining exploration and development company actively pursuing the reopening of its Independence gold and silver mining project in the Battle Mountain Mining District of Nevada. The company’s project, which is located adjacent to the multi-billion dollar Phoenix gold mine of the Newmont Mining Corporation (NEM), contains approximately one million […]

Aethlon Medical, Inc. (AEMD) Creating Innovative Devices to Address Unmet Medical Needs

Aethlon Medical, Inc. (OTCQB: AEMD) creates affinity biofiltration devices to treat life-threatening diseases. The company’s leading therapeutic candidate, the Aethlon Hemopurifier®, is a broad-spectrum therapeutic strategy developed to address drug resistant viral pathogens. To date, the device, which was recently named among ‘The 11 Most Remarkable Advances in Healthcare’ by Time Magazine, has been successfully […]

Uranium Energy Corp. (UEC) Primed for Yellowcake Spot Price Recovery

Uranium Energy is a U.S.-based uranium mining and exploration company operating its fully licensed Hobson Processing Plant as the core of all its South Texas projects, including the Palangana in-situ recovery (ISR) mine, the permitted Goliad ISR project, and the development-stage Burke Hollow ISR project. In addition, Uranium Energy controls a pipeline of advanced-stage projects […]

Definitive Rest Mattress Company (DRMC) Building Shareholder Value through Business Transformation

Definitive Rest Mattress Company is reshaping its business operations in an effort to increase shareholder returns moving forward. In recent months, the company has officially disbanded its previous mattress operations in favor of a new direction focused on metals sales and computer numerical control (CNC) manufacturing. DRMC’s January acquisition of NU Metals Technology, a high […]

ENGlobal Corporation (ENG) Navigates Downturn in Energy Commodity Prices through Refined Business Strategy

In the first quarter of 2015, ENGlobal Corp. (NASDAQ: ENG) demonstrated its versatility, expertly navigating the recent downturn in energy commodity prices despite the market’s softness. “We have pared the Company down to a smaller, more focused operation and reduced the risk profile of the projects we are undertaking, in addition to controlling overhead costs,” […]

 

From Our Blog

Nutriband Inc. (NASDAQ: NTRB) Innovating Abuse-Deterrent Drug Delivery in a Shifting Opioid Landscape

May 9, 2025

A Market Demanding Safer Opioid Solutions The opioid crisis remains a critical public health challenge in the U.S. and globally, prompting a series of new regulatory measures designed to improve safety and reduce misuse. In early 2025, the FDA approved Journavx (suzetrigine), a first-in-class non-opioid painkiller offering patients safer alternatives to opioids. Additionally, opioid manufacturers […]

Rotate your device 90° to view site.